Burroughs Wellcome Navelbine
Executive Summary
Treatment IND for vinorelbine in ambulatory patients with unresectable non-small cell lung cancer who have not had prior chemotherapy begins May 4. An estimated 20% of the 500 patients who are diagnosed in the U.S. with lung cancer daily could be eligible to receive the drug. Approval of Navelbine has been recommended by FDA's Oncology Drugs Advisory Cmte. ("The Pink Sheet" Dec. 20, 1993, p. 10). An NDA for the treatment of advanced breast cancer was submitted on March 31, and Phase II trials for ovarian and prostate cancer are under way
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth